JRB reports grants from BeiGene, Gilead, Loxo/Lilly, MEI Pharma, Sun, Verastem/SecuraBio, and TG Therapeutics; consulting fees from AbbVie, Acerta/AstraZeneca, BeiGene, Bristol Myers Squibb/Juno/Celgene, Catapult, Eli Lilly, Genentech/Roche, Hutchmed, iOnctura, Janssen, Kite, Loxo, MEI Pharma, Morphosys, Nextcea, Novartis, Pfizer, Pharmacyclics, and Rigel; and participation on a data safety monitoring board or advisory board for Invectys and Morphosys. AVD reports grants from Leukemia and Lymphoma Society Clinical Scholar, AstraZeneca, Takeda Oncology, Bayer Oncology, Bristol Myers Squibb, SecuraBio, MEI Pharma, Nurix, and TG Therapeutics; and consulting fees from AstraZeneca, AbbVie, BeiGene, Genentech, TG Therapeutics, Bayer Oncology, Nurix, Oncovalent, MEI Pharma, Lilly Oncology, Incyte, Morphosys, and Pharmacyclics. ASL has served on a speakers bureau for Research to Practice. MSD reports institutional research funding from AbbVie, AstraZeneca, Ascentage Pharma, Genentech, MEI Pharma, Novartis, Surface Oncology, TG Therapeutics, and Verastem; and consulting fees from AbbVie, Adaptive Biosciences, Aptitude Health, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Curio Science, Eli Lilly, Genentech, Janssen, Merck, Ono Pharmaceuticals, Research to Practice, TG Therapeutics, Takeda, and Verastem.